TA
REGN icon

TLS Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

TLS Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-259
Closed -$272K – 19
2024
Q3 		$272K Buy
259
+9
+4% +$10K 0.57% 15
2024
Q2 		$263K Hold
250
– – 0.66% 15
2024
Q1 		$240K Hold
250
– – 0.56% 13
2023
Q4 		$220K Hold
250
– – 0.73% 13
2023
Q3 		$205K Buy
+250
New +$196K 0.83% 13
2023
Q2 		– Sell
-250
Closed -$205K – 17
2023
Q1 		$205K Hold
250
– – 1.05% 13
2022
Q4 		$180K Buy
+250
New +$184K 0.89% 16

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TLS Advisors's REGN Position: Q4 2024 in Review

TLS Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 259 shares — an estimated $272K sold.

TLS Advisors first reported a position in REGN in Q4 2022 and held it in 7 quarters. The position peaked at $272K in Q3 2024. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • TLS Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • TLS Advisors sold 259 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $272K.
  • TLS Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • TLS Advisors's Regeneron Pharmaceuticals position peaked at $272K in Q3 2024.
  • 1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on TLS Advisors's 13F filing for Q4 2024, filed 12 Feb 2025.